Company news

Gilead Sciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access

April 14, 2026

Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead’s First Option Target Exercise

April 9, 2026

Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline

April 6, 2026

Gilead Extends Tender Offer to Acquire Arcellx

March 31, 2026

Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases

March 31, 2026

Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases

March 22, 2026

Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia

March 1, 2026

Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy

February 24, 2026

Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel

February 23, 2026

Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel

February 23, 2026

Stem Cell and Regenerative Therapy Markets, 2022-2025 & Forecast to 2030 Featuring Profiles of Leading Companies - Gilead Sciences, Novartis, Bristol-Myers Squibb, Organogenesis, MiMedx Group and More

February 20, 2026

Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options

February 16, 2026

Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results

February 9, 2026

Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend

February 9, 2026

FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma

February 5, 2026

Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026

January 27, 2026

4D Path Joins Phase II Clinical Trial to Advance Predictive Biomarkers in Bladder Cancer

January 22, 2026

New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer

January 20, 2026

Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration

December 24, 2025

Gilead Sciences to Present at Upcoming Investor Conference

December 21, 2025

Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes

December 21, 2025

Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans

December 18, 2025

Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance

December 17, 2025

Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial

December 14, 2025

Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer

December 8, 2025

Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025

December 6, 2025

Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025

December 5, 2025

Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma

December 5, 2025

Gilead Foundation Commits Over $3 Million to Address Food Insecurity

November 23, 2025

Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa

November 17, 2025

Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial

November 12, 2025

Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression

November 6, 2025

Gilead Provides Update on Phase 3 ASCENT-07 Study

November 6, 2025

Accipiter Biosciences Emerges from Stealth with $12.7 Million in Seed Financing to Deliver de novo Protein Therapies for Complex Diseases

November 6, 2025

Gilead Sciences to Present at Upcoming Investor Conferences

November 3, 2025

Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025

November 2, 2025

Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)

October 30, 2025

Gilead Sciences Announces Third Quarter 2025 Financial Results

October 29, 2025

Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta

October 22, 2025

LYVDELZI® (seladelpar) receives Health Canada approval for the treatment of primary biliary cholangitis

October 21, 2025

Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study

October 18, 2025

Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025

October 18, 2025

Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention

October 14, 2025

Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025

October 12, 2025

Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025

October 8, 2025

Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences

September 29, 2025

Hanmi's Oral Delivery Platform Compound Licensed to Gilead

September 29, 2025

Gilead Foundation Grants $6.5 Million in Commitment to STEM Education

September 24, 2025

Gilead Sciences Commits to Veeva Vault CRM

September 10, 2025

WACO Theater Center Announces Still Here Live Experience In Los Angeles Supported By Gilead Sciences, Inc.

September 8, 2025

← Newer news releases · Older news releases →

Calls

The 5 newest of 26 calls. Every call is listed under its year.

Decks

The 5 newest of 51 decks. Every deck is listed under its year.